174 related articles for article (PubMed ID: 31967382)
1. Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty.
Waltz M; Prince AER; O'Daniel JM; Foreman AKM; Powell BC; Berg JS
J Genet Couns; 2020 Dec; 29(6):949-959. PubMed ID: 31967382
[TBL] [Abstract][Full Text] [Related]
2. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
3. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
[TBL] [Abstract][Full Text] [Related]
4. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
5. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
6. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
Cline MS; Liao RG; Parsons MT; Paten B; Alquaddoomi F; Antoniou A; Baxter S; Brody L; Cook-Deegan R; Coffin A; Couch FJ; Craft B; Currie R; Dlott CC; Dolman L; den Dunnen JT; Dyke SOM; Domchek SM; Easton D; Fischmann Z; Foulkes WD; Garber J; Goldgar D; Goldman MJ; Goodhand P; Harrison S; Haussler D; Kato K; Knoppers B; Markello C; Nussbaum R; Offit K; Plon SE; Rashbass J; Rehm HL; Robson M; Rubinstein WS; Stoppa-Lyonnet D; Tavtigian S; Thorogood A; Zhang C; Zimmermann M; ; Burn J; Chanock S; Rätsch G; Spurdle AB
PLoS Genet; 2018 Dec; 14(12):e1007752. PubMed ID: 30586411
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
8. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
[TBL] [Abstract][Full Text] [Related]
9. "It's not if I get cancer, it's when I get cancer": BRCA-positive patients' (un)certain health experiences regarding hereditary breast and ovarian cancer risk.
Dean M
Soc Sci Med; 2016 Aug; 163():21-7. PubMed ID: 27376595
[TBL] [Abstract][Full Text] [Related]
10. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
11. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
12. BRCA mutation characteristics in a series of index cases of breast cancer selected independent of family history.
Bisgin A; Boga I; Yalav O; Sonmezler O; Tug Bozdogan S
Breast J; 2019 Sep; 25(5):1029-1033. PubMed ID: 31228304
[TBL] [Abstract][Full Text] [Related]
13. Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region.
Elalaoui SC; Laarabi FZ; Afif L; Lyahyai J; Ratbi I; Jaouad IC; Doubaj Y; Sahli M; Ouhenach M; Sefiani A
Breast Cancer Res Treat; 2022 Jul; 194(1):187-198. PubMed ID: 35578052
[TBL] [Abstract][Full Text] [Related]
14. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Evans DG; Shenton A; Woodward E; Lalloo F; Howell A; Maher ER
BMC Cancer; 2008 May; 8():155. PubMed ID: 18513387
[TBL] [Abstract][Full Text] [Related]
15. Clinically Significant Unclassified Variants in
Yoon KA; Park B; Lee BI; Yang MJ; Kong SY; Lee ES
Cancer Res Treat; 2017 Jul; 49(3):627-634. PubMed ID: 27658390
[TBL] [Abstract][Full Text] [Related]
16. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
17. The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.
Pearson EJ; Nair A; Daoud Y; Blum JL
Breast Cancer Res Treat; 2017 Feb; 162(1):59-67. PubMed ID: 28066861
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
19. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
20. Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing.
Liu PF; Zhuo ZL; Xie F; Wang S; Zhao XT
Clin Chim Acta; 2021 May; 516():55-63. PubMed ID: 33476590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]